These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 30561903)

  • 1. Patients with cystic fibrosis having a residual function mutation: Data from the Italian registry.
    Salvatore D; Padoan R; Buzzetti R; Amato A; Giordani B; Ferrari G; Majo F
    Pediatr Pulmonol; 2019 Feb; 54(2):150-157. PubMed ID: 30561903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystic fibrosis with non-G551D gating mutations in Italy: Epidemiology and clinical characteristics.
    Salvatore D; Carnovale V; Majo F; Padoan R; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
    Pediatr Pulmonol; 2021 Feb; 56(2):442-449. PubMed ID: 33219628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Italian Cystic Fibrosis Registry (ICFR). Report 2021-2022].
    Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
    Epidemiol Prev; 2024; 48(2 Suppl 2):1-41. PubMed ID: 38742380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Italian Cystic Fibrosis Registry (ICFR). Report 2017-2018].
    Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
    Epidemiol Prev; 2021; 45(3 Suppl 1):1-37. PubMed ID: 34132083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Italian Cystic Fibrosis Registry (ICFR). Report 2015-2016].
    Giordani B; Amato A; Majo F; Ferrari G; Quattrucci S; Minicucci L; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
    Epidemiol Prev; 2019; 43(4S1):1-36. PubMed ID: 31370382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
    Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
    Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data.
    Keogh RH; Szczesniak R; Taylor-Robinson D; Bilton D
    J Cyst Fibros; 2018 Mar; 17(2):218-227. PubMed ID: 29311001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical phenotype of cystic fibrosis patients with the G551D mutation.
    Comer DM; Ennis M; McDowell C; Beattie D; Rendall J; Hall V; Elborn JS
    QJM; 2009 Nov; 102(11):793-8. PubMed ID: 19734299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.
    Donaldson SH; Pilewski JM; Griese M; Cooke J; Viswanathan L; Tullis E; Davies JC; Lekstrom-Himes JA; Wang LT;
    Am J Respir Crit Care Med; 2018 Jan; 197(2):214-224. PubMed ID: 28930490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
    Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
    Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Presentation of the c.3844T>C (p.Trp1282Arg, W1282R) Variant in Russian Cystic Fibrosis Patients.
    Petrova NV; Kashirskaya NY; Krasovskiy SA; Amelina EL; Kondratyeva EI; Marakhonov AV; Vasilyeva TA; Voronkova AY; Sherman VD; Ginter EK; Kutsev SI; Zinchenko RA
    Genes (Basel); 2020 Sep; 11(10):. PubMed ID: 32992607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients.
    Schippa S; Iebba V; Santangelo F; Gagliardi A; De Biase RV; Stamato A; Bertasi S; Lucarelli M; Conte MP; Quattrucci S
    PLoS One; 2013; 8(4):e61176. PubMed ID: 23613805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of Lung Function Decline in People with Cystic Fibrosis Having a Residual Function Gene Mutation.
    Sawicki GS; Konstan MW; McKone EF; Moss RB; Lubarsky B; Suthoff E; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan WJ; Duncan ME; Yang Y
    Pulm Ther; 2022 Dec; 8(4):385-395. PubMed ID: 36319933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Italian Cystic Fibrosis Registry (ICFR). Report 2019-2020].
    Campagna G; Amato A; Majo F; Ferrari G; Quattrucci S; Padoan R; Floridia G; Salvatore D; Carnovale V; Puppo Fornaro G; Taruscio D; Salvatore M;
    Epidemiol Prev; 2022; 46(4 Suppl 2):1-38. PubMed ID: 36102313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.
    Padoan R; Bassotti A; Seia M; Corbetta C
    Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.
    Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M
    PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.
    Derichs N; Mekus F; Bronsveld I; Bijman J; Veeze HJ; von der Hardt H; Tummler B; Ballmann M
    Pediatr Res; 2004 Jan; 55(1):69-75. PubMed ID: 14605249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene.
    Dupuis A; Keenan K; Ooi CY; Dorfman R; Sontag MK; Naehrlich L; Castellani C; Strug LJ; Rommens JM; Gonska T
    Genet Med; 2016 Apr; 18(4):333-40. PubMed ID: 26087176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Italian Cystic Fibrosis Register - Report 2010].
    Amato A; Ferrigno L; Salvatore M; Toccaceli V;
    Epidemiol Prev; 2016; 40(2 Suppl 2):1-47. PubMed ID: 27291389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.